Background {#Sec1}
==========

As has been seen in many areas around the world, the number of malaria cases reported in the Lao People's Democratic Republic (Lao PDR) has significantly decreased over the last decade \[[@CR1]\]. Encouraged by this success, the Laos Ministry of Health aims to eliminate malaria by 2030 \[[@CR2]\]. This undertaking is threatened by the recent emergence and spread of *Plasmodium falciparum* strains resistant to first-line anti-malarials, the artemisinin‐based combination therapy (ACT) \[[@CR3]\]. The current steady decline in *P. falciparum* transmission may not continue in Lao PDR and other countries in the Greater-Mekong Subregion (GMS). Moreover, should multidrug resistance continue to spread through Asian countries unchecked, its inevitable arrival on the African continent will lead to a public health disaster \[[@CR4], [@CR5]\]. In response to this threat, the current World Health Organization (WHO) strategy is to eliminate *P. falciparum* malaria from the GMS with alacrity \[[@CR6]\]. The WHO Global Technical Strategy for malaria 2016--2030 includes: (1) ensuring universal access to malaria prevention, diagnosis and treatment; (2) accelerating efforts towards elimination and attainment of malaria-free status; (3) transforming malaria surveillance into a core intervention.

The current coverage of early detection and treatment, along with the distribution of long-lasting insecticide-treated bed nets (LLIN), may be insufficient to achieve this strategy. There is an urgent need to consider additional alternative strategies to accelerate the elimination of malaria in countries like Lao PDR, and while ACT is still generally effective \[[@CR7]\].

One such strategy is the elimination of the entire parasite reservoir by the presumptive treatment of all residents in malaria-endemic areas. Mass drug administrations (MDA) have successfully eliminated malaria on a Pacific island \[[@CR8]\], but require the participation of the majority of the community. MDA provide only temporary (4--6 months) reductions in malaria cases if coverage is less than 80% or if infected people re-import malaria into the area \[[@CR9], [@CR10]\]. To interrupt transmission permanently, additional interventions would probably be needed, such as the inclusion of mass vaccination using RTS,S/AS01 given in three doses at monthly intervals \[[@CR1]\]. This vaccine does not provide life-long, complete protection but it is efficacious for several months. Protection wanes to around 50% at 200 days after the third dose \[[@CR11]\]. A combined Mass Vaccination and Drug Administration (MVDA) clears the parasite reservoir in a population and protects participants for a limited period against infections. This parasite-free window provides sufficient time to clear on-going sources of parasite transmission such as new arrivals in the community, and allows for the rolling out of the intervention to surrounding villages, thus eliminating future sources of malaria transmission.

It is now widely accepted that the elimination of malaria will require several stages of programmatic scale-up \[[@CR12]\]. Current and novel tools and their effective use have been highlighted as essential to achieve malaria eradication. For example, the Bill and Melinda Gates Foundation has urged the malaria community to consider the following three aims \[[@CR13]\]:Complete detection: health workers need to find all individuals who have the parasite in their blood, regardless of whether they are symptomatic or not.Complete cure: using treatments that clear all malaria parasites.Complete prevention: reducing opportunities for mosquitoes to transmit parasites to the human host.

Each of these aims will require new products to fully meet the challenge. For relatively low transmission settings like those in the GMS, and given the urgency of the drug resistance issue in this region, there is a compelling argument that these aims could be met with existing tools which provide:Partial detection in the form of village health volunteers (VHV) screening new arrivals with high sensitivity rapid diagnostic tests (HS RDT).Partial cure with ACT treating most clinical infections but with some treatment failure, and focal MDA to treat most infections at three time points.Partial prevention, with LLIN offering a reduction of 30% in the force of infection \[[@CR14]\], and RTS,S mass vaccination offering temporary and partial protection against infection.

The sequential inclusion of each component to build an integrated strategy was done because, with the exception of MDA and RTS,S, these interventions are routine in Lao PDR. MDA is, however, being trialled \[[@CR15]\]. The addition of RTS,S is also operationally highly feasible since it can be delivered through the same mechanism.

Here, a simple mathematical model was used to evaluate whether a suite of detection and treatment approaches for malaria elimination can eliminate malaria in one specific geographically defined area, namely Savannakhet province, Lao PDR. The model structure used was similar to that of the mathematical model which predicted the current emergence of multi-drug resistance in the GMS \[[@CR16], [@CR17]\]. Such model structures have been used as tools to support policy making \[[@CR16]--[@CR19]\] and have repeatedly proven to be both agile and qualitatively accurate for malaria strategy exploration \[[@CR20], [@CR21]\]. When exploring combinations of novel interventions in settings where data are sparse, simple models can be applied more readily than their more accurate, but data-hungry, complex counterparts, and are adequate for preliminary simulations to support the design of field trials where more accurate data could be collected. For example, in 2012 a model predicted that three rounds of MDA in 3 months would be an optimal MDA strategy \[[@CR22]\], a design that is currently under trial in the GMS \[[@CR23]\]. Previous modelling work has indicated that the delivery of vaccination simultaneously during an elimination could act to increase the impact of the intervention, while simultaneously slowing the spread of anti-malarial drug resistance \[[@CR21]\]. The addition of vaccination is, therefore, included in the elimination package explored here for Savannakhet.

Methods {#Sec2}
=======

Study site {#Sec3}
----------

Savannakhet (Fig. [1](#Fig1){ref-type="fig"}), the most populated province in Lao PDR \[[@CR24]\], was used to simulate the impact of combined interventions (Fig. [2](#Fig2){ref-type="fig"}). Among the 18 provinces of Lao PDR, Savannakhet has the third highest malaria incidence \[[@CR25]\]. A survey conducted in 18 rural villages in Savannakhet in 2015, using an ultrasensitive quantitative PCR approach (uPCR), detected asymptomatic *Plasmodium* infections in 175 out of 888 samples (20%), of which 3.6% were *P. falciparum* \[[@CR25]\]. Most villages in Savannakhet are relatively accessible and malaria elimination is a high priority for the local government. Starting in April 2016, a pilot project to eliminate malaria was initiated in four villages in the Nong district of Savannakhet. The project showed that MDA in Savannakhet is both feasible and well accepted; more than 80% of targeted villagers participated in the three rounds of drug administration \[[@CR26]\].Fig. 1Savannakhet Province in Lao People's Democratic Republic Fig. 2Timeline for Mass Vaccination and Drug Administration (MVDA), booster administration, and follow-up

The interventions {#Sec4}
-----------------

Early diagnosis and adequate treatment (EDAT) involves comprehensive case management that includes the use of appropriate standard rapid diagnostic tests (RDT) to detect symptomatic *P. falciparum* and *Plasmodium vivax* infections and, if available, glucose-6-phosphate dehydrogenase (G6PD) deficiency, plus treatment following government guidelines, which consists of ACT for *P. falciparum* and a schizontocidal drug combined with 14 days of primaquine therapy for *P. vivax*. LLIN remain the only widely recommended and used form of vector control in Lao PDR. The impact of LLIN is limited by the outdoor, daytime biting behaviour of the important local malaria vectors \[[@CR27], [@CR28]\]. In the absence of alternative, proven vector control methods, access for every resident to an intact LLIN will be part of the strategy. EDAT and LLIN provision will be implemented by VHV in each village in the study area. Other roles of the VHV include the reporting of diagnosed and treated malaria cases, and the engagement of the wider community in the malaria elimination project. It is assumed that the recruitment, training, and deployment of new VHV will take 1 year.

Communities with a high number of malaria cases (as reported by VHV) will be targeted for MDA and mass vaccination (MVDA). The current MDA regimen consists of three rounds of three doses of dihydroartemisinin/piperaquine (DHA-PPQ, 40/320 mg) and a single low dose of primaquine (0.25 mg/kg irrespective of G6PD status for gametocidal action against *P. falciparum*) with each round. One dose of RTS,S/AS01 will be added to each round of anti-malarial drugs, and there will be a booster dose after 1 year (Fig. [2](#Fig2){ref-type="fig"}).

Once all of the *P. falciparum* infections have been cleared, there remains a risk for re-importation of infections. Visitors and immigrants will be asked to provide a finger prick blood sample for rapid testing with a new generation lateral flow assay (HS RDT such as Alere Malaria Ag *P. f.*) which has 44% sensitivity and 99.8% specificity in low-transmission setting when uPCR is taken as Ref. \[[@CR12]\]. Any infected newcomers will be offered appropriate treatment for their infection.

The modelling tool {#Sec5}
------------------

A simple, web-based deterministic compartmental modelling tool, developed using the R programming language and software \[[@CR29]\] with shiny \[[@CR30]\], deSolve \[[@CR31]\], TSA \[[@CR32]\] and Rcpp \[[@CR33]\] packages, was used for this modelling exercise. The model is an SITR (Susceptible-Infected-Treatment-Recovered) model that includes eight compartments, in which different levels of infected states are included to account for the asymptomatic malaria cases. Cases in the "Infected, Asymptomatic & Patent" (I~A~) compartment will be detectable by microscopy and RDT, whereas cases in "Infected, Asymptomatic & Sub-microscopic" (I~U~) will not be detected with such tests. The model structure for infection dynamics and treatment dynamics is illustrated in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}.Fig. 3Model structure Fig. 4Dynamics of the model

The modelling tool can be accessed at \[[@CR34]\].

Various baseline and intervention scenarios can be set up using the sliders on the tool. The increase in coverage and the addition of newer interventions are modelled to start after year 2018. Based on any particular set-up, the model will predict the expected monthly incidence of both detected and total clinical *P. falciparum* malaria cases per 1000 population per month. It will also predict the expected underlying true prevalence of *P. falciparum* as a percentage of the total population of the chosen subnational area. When the server completes the model run, the results are plotted almost instantaneously.

The modelled package of interventions comprises the following three aims:Ensure universal access to malaria prevention, diagnosis and treatment.90% coverage of LLIN modelled as a reduced force of infection dependent on the coverage and the efficacy of LLIN in the GMS setting.70% of all clinical cases receive early diagnosis and adequate treatment (EDAT) with ACT, modelled as the diversion of the flow of newly infected cases from entering into their respective infection states to the treated state.Accelerate efforts towards elimination and attainment of malaria-free status.Three monthly rounds of MDA targeted on higher prevalence villages. The model assumes that given the linkage between villages due to population mobility, this would translate to an effective coverage of the at-risk population of 50%.The addition of mass vaccination using the RTS,S vaccine to the same population which received the MDA, with three monthly doses of the vaccine delivered simultaneously with the MDA rounds. A booster dose of the vaccine is added after 1 year. Vaccinated individuals are modelled as being partially protected against infection for a period of time before regaining full susceptibility to infection.Transform malaria surveillance into a core intervention.To prevent re-importation of malaria following elimination, the incoming population is modelled as undergoing screening upon entry using HS RDT, and treated if testing positive. This is manifested as a reduction in the rates of importation of infection, depending on the coverage of this intervention and the sensitivity of the test used to each type of infection.

The source code for the modelling tool can be found here \[[@CR35]\].

Interpretation of the results of the modelling tool {#Sec6}
---------------------------------------------------

The output of the modelling tool has two graphs. The first one (Fig. [5](#Fig5){ref-type="fig"}) plots the model's prediction for the monthly incidence of clinical malaria cases per 1000 population, making a comparison between the baseline scenario, which is represented by grey lines, and the intervention scenario, which is represented by blue lines. The number of confirmed clinical cases is represented by the lower boundary of the oscillating line, and the total number of clinical cases, inclusive of the clinical cases which are not detected/diagnosed, is represented by the upper boundary of the oscillating line. The number of confirmed cases will be less than the true clinical burden since the model assumes that not all clinical cases are detected and treated by the health system. This is the reason why, under the baseline scenario, the distance between the upper and lower boundary is large. The more cases that are detected by the health system, the more the confirmed cases will reflect the model's prediction of the true clinical burden. Thus, the range between the upper and lower boundary is narrowed when EDAT coverage is increased.Fig. 5Interpretation of the monthly incidence of malaria from the output of the modelling tool. The incidence is indicated as a range, in which the lower border indicates the estimated incidence of *P. falciparum* detected by passive surveillance, and the upper border the estimated incidence of all infections. Interruption of transmission is achieved when the incidence no longer reaches the elimination threshold

The second output of the modelling tool (Fig. [6](#Fig6){ref-type="fig"}) shows the model's prediction for true prevalence. This is defined as the percentage of the population that has a clinical infection (I~C~), a microscopically-detectable asymptomatic infection (I~A~), or a microscopically-undetectable asymptomatic infection (I~U~). It is intended to represent the entire transmission reservoir associated with each scenario.Fig. 6Interpretation of the prevalence of malaria from the output of the modelling tool

Setting up the model baseline and intervention scenarios for Savannakhet {#Sec7}
------------------------------------------------------------------------

First, a baseline scenario suitable for Savannakhet was set up, the parameters of which can be found in Table [1](#Tab1){ref-type="table"}. According to the Centre for Malariology, Parasitology and Entomology, Lao PDR, this reflects an Annual Parasite Incidence (API) of about 10 detected clinical cases of malaria per 1000 population per year \[personal communication\], and a mean parasite prevalence of 3.5% \[[@CR25]\]. It was assumed that the baseline LLIN coverage was relatively high (70%), while the baseline access to treatment for clinical cases was assumed to be relatively low (25%). Then, the baseline scenario was sequentially augmented with a series of components of a simulated integrated *P. falciparum* elimination package. The coverage of LLIN was increased, resulting in a reduction in the force of infection in those covered by 30% \[[@CR14]\]. Early detection and treatment was increased. MDA reached a coverage of 80--95% of a sub-population within three months of each year \[[@CR9]\]. The sub-population was assumed to represent 50% of the infectious reservoir. Vaccination using the RTS,S vaccine \[[@CR36]\] was included, assuming a peak protective effect of 92% for those who received all three doses of the vaccine, with the protective effect waning to 50% over the following 200 days \[[@CR11]\]. The screening of 90% of individuals entering Savannakhet with a high sensitivity RDT was modelled as a reduction in the importation of infected individuals proportional to the assumed sensitivity of the test to each type of infection.Table 1Assumptions for the baseline scenario in SavannakhetParameterValueUnitBaseline API10Per 1000 per yearNumber of mosquito bites per human per night (peak season)20Per night per human% of all infections that are caught outside the village (forest)30%Baseline % of all clinical cases treated25%Baseline coverage of LLIN70%% of infections averted due to ownership of LLIN30%Baseline coverage of IRS0%% reduction in biting rate due to IRS15%Imported clinical cases1Per 1000 per yearImported asymptomatic microscopically detectable carriers1Per 1000 per yearImported asymptomatic microscopically undetectable carriers1Per 1000 per year% of cases failing treatment in 2018 and before5%% of cases failing treatment in 201915%% of cases failing treatment in 2020 and after30%These parameters are set up in the "Baseline" tab in the modelling tool

The assumptions on which the model is based are provided in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. Elimination is defined as the reduction of detected clinical cases to below the elimination threshold of one case per 1000 population per year. The detailed model structure, equations, and its remaining parameterisation based on \[[@CR20], [@CR37]--[@CR45]\] can be found in Additional file [1](#MOESM1){ref-type="media"}.Table 2Assumptions for the increasing coverage of LLIN and EDAT (universal coverage scenario)ParameterValueUnitYears to scale up EDAT1YearNew % of all clinical cases treated70%Years to universal access to LLIN1YearNew bed net use of LLIN90%These parameters are from the "Interventions currently available" tab in the modelling tool Table 3Assumptions for the focal MDA in addition to universal coverage scenario in Table [2](#Tab2){ref-type="table"}ParameterValueUnitEffective population coverage (entire province) of focal MVDA in round 150%Effective population coverage (entire province) of focal MVDA in round 250%Effective population coverage of focal MVDA in round 350%Timing of 1st roundSeptember 2018Timing of 2nd roundOctober 2018Timing of 3rd roundNovember 2018Months to complete each round6MonthsDays prophylaxis provided by the ACT30DaysThese parameters are from the "Interventions under trial: Focal MVDA (hotspot)" tab in the modelling tool Table 4Assumptions for the MVDA in addition to those in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}ParameterValueUnit% protective efficacy of RTS,S with 1st dose75%% protective efficacy of RTS,S with 2nd dose80%% protective efficacy of RTS,S with 3rd dose92%Half-life of vaccine protection90daysThese parameters are from the "Interventions under trial: Focal MVDA (hotspot)" tab in the modelling tool Table 5Assumptions for the mass screening and treatment of imported cases in addition to Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}ParameterValueUnitYears to scale up MSAT1YearsNew coverage of MSAT90%Sensitivity HS RDT (clinical infections)99%Sensitivity HS RDT (asymptomatic, microscopically detectable)87%Sensitivity HS RDT (asymptomatic, microscopically undetectable)44%These parameters are from the "Interventions under trial: Focal MSAT (mobile)" tab in the modelling tool

Results {#Sec8}
=======

The passively detected falciparum malaria incidence in villages in Savannakhet, Lao PDR is estimated on average to be 10 cases per 1000 population per year and, assuming the parameter values in Table [1](#Tab1){ref-type="table"}, the *P. falciparum* infection prevalence is around 3.5% (Fig. [7](#Fig7){ref-type="fig"}). VHV are established and distribute LLIN to ensure complete coverage, as well as providing early, accurate diagnosis of malaria and appropriate treatment (Fig. [8](#Fig8){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). This intervention is predicted to slowly reduce the incidence of falciparum infections, but not to elimination levels due to the constant influx of malaria infection imported from outside Savannakhet.Fig. 7The baseline estimates illustrate the seasonal variability in the presence of spreading anti-malarial resistance Fig. 8Increasing the coverage of community health workers who distribute LLIN and provide EDAT

The addition of MDA is predicted to accelerate the reduction in both prevalence and incidence in a matter of years (Fig. [9](#Fig9){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}), to the levels predicted to be achievable with universal EDAT and LLIN. Re-importation of infections may result in the return to pre-MDA incidence levels in the absence of aggressive case management by VHV. Adding mass vaccination is predicted to interrupt transmission (Fig. [10](#Fig10){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). The added benefit of adding mass vaccination to MDA is further explored in Additional file [1](#MOESM1){ref-type="media"}: Figs. S4 and S5. Clinical malaria would then be predicted to drop below the elimination threshold, after which the re-importation of cases would rekindle transmission, resulting in a slow but steady increase in incidence and prevalence.Fig. 9Addition of mass drug administrations (MDA) Fig. 10Addition of vaccinations to MDA (MVDA)

The remaining transmission is driven by imported cases, necessitating the immediate detection and treatment of clinical and subclinical infections entering villages. The acceptance of presumptive anti-malarial therapy is likely to wane with the steady disappearance of clinical malaria. To prevent the return of infections, new arrivals will be screened with HS RDT. Any person found to be infected would be treated with a full course of appropriate anti-malarials. This final step is predicted to prevent reintroduction of infections, and in the model is critical for the permanent interruption of transmission (Fig. [11](#Fig11){ref-type="fig"}, Table [5](#Tab5){ref-type="table"}).Fig. 11Stopping the importation of infection through screening and treatment of visitors and immigrants

Discussion {#Sec9}
==========

The model shows that a sequence of interventions, namely universal access to early diagnosis and adequate treatment, improved access to insecticide-impregnated bed nets, three monthly rounds of MDA together with RTS,S vaccination followed by a booster dose of vaccine, and screening and treatment of imported cases, could eliminate falciparum malaria from Savannakhet over a period of 3 years. Each of these interventions is essential; skipping vaccinations and following MDA with screening and treating newcomers, for example, is insufficient to interrupt transmission.

The findings from this study suggest a need for a multiphasic approach to malaria elimination, in which each phase builds on the achievements of the earlier phase. VHV are a critical foundation for this elimination \[[@CR46], [@CR47]\]. Not only do they manage incident malaria cases, their remit also includes the distribution of LLIN to ensure that every resident has access to one, and the timely reporting of malaria cases to the control programme. The additional phases of the malaria elimination programme depend on the services provided by VHV, along with the community engagement efforts developed by VHV together with other malaria project team members. The MDA and vaccination campaigns can only succeed if a large majority of residents participate. Engaging the community in such activities requires trust, especially in the absence of a complete understanding of the complexities of malaria elimination. Only if a VHV has such trust is it be likely that most villagers would participate in MDA and any subsequent mass vaccination campaigns \[[@CR48]\]. The model showed that the clearance of malaria would last for just one season in the face of constant reintroduction of infections. Only a rigorous screening programme of newcomers can prevent the resurgence of infections after the initial clearing. As mentioned earlier, it seems unlikely that most newcomers would volunteer to presumptive therapy without a positive diagnostic test. The recent development of HS RDT \[[@CR12], [@CR20]\] could therefore be a key element in preventing the reintroduction of infections.

The stacking of sequential interventions requires considerable human and financial resources. However, the combination of interventions suggested in this study can accelerate malaria elimination, particularly in the face of the threat presented by the diminishing efficacy of the tools required for a slow but steady elimination. The early treatment of malaria cases will become increasingly challenging with the spread of multi-drug resistant *P. falciparum* strains. LLIN may also lose their protective efficacy due to the spread of insecticide resistant malaria vectors.

This model was set up to estimate the effect of a variety of combinations of interventions on *P. falciparum* transmission. The elimination of *P. vivax* is equally desirable, but complicated by hypnozoites, the liver stages of *P. vivax*, which can cause a relapse in the absence of a radical cure with 8-aminoquinolines. It is generally assumed that an RTS,S-like vaccine does not provide protection against *P. vivax* infections. The appropriate treatment of all clinical vivax malaria episodes with an 8-aminoquinoline will ultimately result in the elimination of *P. vivax.* The timeframe to eliminate *P. vivax* infection will be longer than that for *P. falciparum*.

Conclusions {#Sec10}
===========

This study found that a sequential implementation of five interventions would be needed to eliminate *P. falciparum* infections from Savannakhet. Such an undertaking carries considerable operational challenges, and has not yet been implemented elsewhere. Preparatory studies to allow for the evaluation of such a strategy of stacking five interventions, including vaccination, are currently underway in Savannakhet.

Additional file {#Sec11}
===============

**Additional file 1.** Model structure and equations.
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